Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Le Mercier

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Revue Medicale De Bruxelles|May 20, 2017
[Next generation sequencing]M Le Mercier, N D'Haene, S Rorive, et al.
Revue Medicale De Bruxelles|May 20, 2017
[How molecular biology can improve the clinical diagnosis of gliomas?]N D'Haene, O Blanchard, N De Nève, et al.
British Journal of Cancer|August 21, 2015
IGF-IR: a new prognostic biomarker for human glioblastomaC Maris, N D'Haene, A-L Trépant, et al.
Journal of Neuro-Oncology|March 4, 2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Vandervorst, et al.
Journal of Neuro-Oncology|October 9, 2017
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Bouttens, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Revue Medicale De Bruxelles|May 20, 2017
[Next generation sequencing]M Le Mercier, N D'Haene, S Rorive, et al.
Revue Medicale De Bruxelles|May 20, 2017
[How molecular biology can improve the clinical diagnosis of gliomas?]N D'Haene, O Blanchard, N De Nève, et al.
British Journal of Cancer|August 21, 2015
IGF-IR: a new prognostic biomarker for human glioblastomaC Maris, N D'Haene, A-L Trépant, et al.
Journal of Neuro-Oncology|March 4, 2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Vandervorst, et al.
Journal of Neuro-Oncology|October 9, 2017
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Bouttens, et al.
Pageof 1